MR Antagonist and LSD1

Running, not enrolling · Phase 4

Conditions studied: Hypertension, Mineralocorticoid Excess

In brief

Lysine specific demethylase-1 (LSD1) is an epigenetic regulator of gene transcription involved in the pathophysiology of elevated blood pressure and likely renal damage in Blacks. This project investigates whether a genetically driven anti-hypertensive approach proves superior in controlling blood pressure and mitigating renal injury in Blacks who carry the risk allele for LSD1 (rs587168). The findings of these investigations may lead to a new approach in treating a subset (\~30%) of the essential hypertension population (Black LSD1 risk allele hypertensives).

Key facts

Study ID

NCT04840342

Run by

Brigham and Women's Hospital

People needed

300

Starts

2022-02-03

Expected to finish

2026-06-01

Last updated by the study team

2026-04-29

Who can join

Age: 17 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• untreated as well as currently treated hypertensives
• rs587168 allele carriers
• not on more than two anti-hypertensives
• normal renal, metabolic, electrolyte, and CBC laboratory tests
• self-identified Black race
• age >17 yrs.

You may not qualify if…

• known cardiac disease other than HTN
• renal, circulatory or neurologic diseases
• diabetes
• smoking
• secondary HTN as indicated by history, physical examination or screening blood and urine tests
• smoking
• any drug therapy, except for anti-hypertensives and stable thyroid medication replacement

Where it is running

• Brigham and Women's — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.